Pfizer has again been sued over a deal it struck years ago that delayed generic competition to Lipitor, still the best-selling drug of all time. The lawsuit comes from national pharmacy chain CVS, which claims the deal cost it hundreds of millions of dollars.
The 101-page complaint, filed last week in federal court in New Jersey, names Pfizer and Indian drugmaker Ranbaxy Laboratories, which was bought out in 2015 by Sun Pharmaceutical.
The complaint accuses Pfizer of striking a pay-for-delay deal with the generics maker that kept Lipitor copycats off the market for 20 months, depriving consumers of billions of dollars in savings and costing CVS hundreds of millions in extra costs. Because Ranbaxy had six months of exclusivity through its so-called first-to-file status, other generics could not come into the market until the generics maker launched its own copy. Lipitor had 2010 US sales of US$5.3 billion.
Full Content: Law 360
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Regulator Proposes State-Backed Formula to Lower Baby Formula Costs
Nov 10, 2024 by
CPI
Justice Department Probes Alleged Price-Fixing in PVC Pipe Industry
Nov 10, 2024 by
CPI
US Imposes Ban on TSMC’s Advanced Chip Exports to China Amid AI Concerns
Nov 10, 2024 by
CPI
Vanderbilt QB Sues NCAA Over Junior College Eligibility Rules
Nov 10, 2024 by
CPI
Trump’s Transition Team Prepares to Reshape FTC Leadership and Antitrust Agenda
Nov 10, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI